INS and cancer: In a retrospective observational study using data from the General Practice Research Database (GPRD, the predecessor of CPRD), van Staa and colleagues observed increased cancer risk for insulin versus metformin monotherapy in the first six months after initiation (adjusted relative rate 1.79, 95% CI 1.53–2.10), but this decreased with time from initiation, indicating protopathic bias [26].